血管紧张素转化酶抑制剂/血管紧张素Ⅱ受体拮抗剂治疗Alport综合征的理论及实践

Theory and practice of angiotensin converting enzyme inhibitor/angiotensinⅡreceptor blocker treatment for Alport syndrome

Alport综合征(AS)是一种遗传性Ⅳ型胶原相关性疾病,可累及肾脏、耳蜗和眼睛等,最终导致器官功能受损和终末期肾病,目前尚缺乏病因性疗法。作为对症性治疗药物,血管紧张素转化酶抑制剂(ACEI)和血管紧张素Ⅱ受体拮抗剂(ARB)展现出令人满意的疗效,可降低蛋白尿,延缓肾功能恶化和终末期肾病进程,并且早期治疗患者获益更大。本文回顾了ACEI/ARB在AS相关动物模型和临床试验中的研究进展,旨在促进临床规范应用ACEI/ARB治疗AS,使更多患者获益。

Alport syndrome(AS)is an inherited typeⅣcollagen-related disorder that can involve the kidneys,cochlea,eyes and eventually lead to impaired organ function and end-stage renal disease.There is still a lack of etiologic therapy.As a symptomatic therapy,angiotensin converting enzyme inhibitors(ACEI)&angiotensinⅡreceptor blockers(ARB)have shown encouraging therapeutic effects in reducing proteinuria and delaying the progression of renal failure,patients would benefit more from early clinical intervention.We reviewed the research progress of ACEI/ARB therapy in animal models and clinical trials,aiming to promote the standardized clinical use of ACEI/ARB to benefit more AS patients.